Daxor Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DXR research report →
Companywww.daxor.com
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
- CEO
- Michael Richard Feldschuh
- IPO
- 1983
- Employees
- 37
- HQ
- Oak Ridge, TN, US
Price Chart
Valuation
- Market Cap
- $57.19M
- P/E
- 6.26
- P/S
- 380.76
- P/B
- 1.25
- EV/EBITDA
- 6.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -57.45%
- Op Margin
- 6174.23%
- Net Margin
- 6105.29%
- ROE
- 22.50%
- ROIC
- 20.16%
Growth & Income
- Revenue
- $503.42K · -76.37%
- Net Income
- $9.17M · 1609.71%
- EPS
- $1.84 · 1572.73%
- Op Income
- $9.19M
- FCF YoY
- -2452.56%
Performance & Tape
- 52W High
- $14.76
- 52W Low
- $7.57
- 50D MA
- $10.30
- 200D MA
- $11.92
- Beta
- 0.29
- Avg Volume
- 11.19K
Get TickerSpark's AI analysis on DXR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 8, 26 | Feldschuh Michael Richard | buy | 1,000 |
| Mar 31, 26 | Michel Robert J | buy | 1,000 |
| Mar 20, 26 | Jefferies John | buy | 2,285 |
| Mar 20, 26 | Jefferies John | buy | 3,656 |
| Dec 9, 25 | Michel Robert J | buy | 3,000 |
| Dec 9, 25 | Feldschuh Jonathan Adam | buy | 18,000 |
| Nov 12, 25 | Jefferies John | buy | 2,344 |
| Sep 30, 25 | Jefferies John | other | 0 |
| Sep 30, 25 | Jefferies John | other | 448 |
| Sep 30, 25 | Jefferies John | other | 406 |
Our DXR Coverage
We haven't published any research on DXR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DXR Report →